ForeverGreen Worldwide earns BSCG's anti-doping certification for PowerStrips

NewsGuard 100/100 Score

ForeverGreen Worldwide Corporation (OTCBB: FVRG), a leading direct marketing company and provider of health-centered products, today announced the company has received an anti-doping certification from the Banned Substances Control Group (BSCG) for PowerStrips, indicating the product is free of banned substances. BSCG's certification process involves analytical testing, a review of production processes and quality control. PowerStrips are listed as a Class 1 medical device for the temporary relief of minor aches and pains.

The BSCG and founder, Dr. Don Catlin, are known as the leader and gold standard in dietary supplement certification, and work with manufacturers, ingredient suppliers, and individual teams and athletes. They test dietary supplements and ingredients to ensure quality and possibility of contamination with drugs that could lead to positive drug tests or health concerns.

"PowerStrips went through a lengthy, unrivaled and complex process in order to obtain this critical certification. Being certified free of banned substances and also drug free is a very important step in making ForeverGreen a premium company in the industry. This will significantly increase our target market as it opens up the world of sports and athletes who are exceptionally careful about products they put on or in their bodies and require this type of certification before use," commented General Manager, Craig Smith.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study shows antipsychotic drugs increase health risks in dementia patients